The influence of cytotoxicity of macromolecules and of VEGF gene modulated vascular permeability on the enhanced permeability and retention effect in resistant solid tumors

被引:55
作者
Minko, T
Kopeckova, P
Pozharov, V
Jensen, KD
Kopecek, J [1 ]
机构
[1] Univ Utah, Dept Pharmaceut & Pharmaceut Chem, Salt Lake City, UT 84112 USA
[2] Univ Utah, Dept Bioengn, Salt Lake City, UT 84112 USA
[3] Olympus Res, Salt Lake City, UT USA
关键词
HPMA copolymer; enhanced permeability and retention effect; VEGF gene; antitumor activity; necrosis; doxorubicin;
D O I
10.1023/A:1007500412442
中图分类号
O6 [化学];
学科分类号
0703 ;
摘要
Purpose. To study the influence of cytotoxicity of macromolecules, VEGF gene expression, and vascular permeability on the enhanced permeability and retention (EPR) effect. Methods. Mice bearing xenografts of A2780 multidrug, resistant human ovarian carcinoma were treated by free doxorubicin (DOX) and N-(2-hydroxyp ropyl)methacrylamide (HPMA) copolymer-bound DOX (P(GFLG)-DOX), Texas Red (P-TR), and FITC (P-FITC). Antitumor activity, drug distribution in tumor, vascular permeability, VEGF gene expression, and DNA fragmentation were studied. Results. The accumulation of free DOX led to the VEGF gene overexpression and increased the vascular permeability, which in turn enhanced the drug accumulation in the same location. This positive feedback loop led to a highly inhomogeneous distribution of the drug within the turner. In contrast, P(GFLG)-DOX down-regulated the VEGF gene and decreased vascular permeability. This negative Feedback seemed to prevent additional drug accumulation in dead necrotic tissue, resulting in a more uniform drug distribution and enhanced the antitumor activity P(OFLG)-DOX. Conclusions. The EPR effect significantly differed for macromolecules containing DOX when compared to macromolecules without drug. The cytotoxicity of P(GFLG)-DOX amplified the EPR effect, led to a more homogenous distribution of the drug, increased the average drug concentration in tumor and augmented its efficacy.
引用
收藏
页码:505 / 514
页数:10
相关论文
共 32 条
[1]   Selective ablation of immature blood vessels in established human tumors follows vascular endothelial growth factor withdrawal [J].
Benjamin, LE ;
Golijanin, D ;
Itin, A ;
Pode, D ;
Keshet, E .
JOURNAL OF CLINICAL INVESTIGATION, 1999, 103 (02) :159-165
[2]   VASCULAR-PERMEABILITY FACTOR (VASCULAR ENDOTHELIAL GROWTH-FACTOR) GENE IS EXPRESSED DIFFERENTIALLY IN NORMAL-TISSUES, MACROPHAGES, AND TUMORS [J].
BERSE, B ;
BROWN, LF ;
VANDEWATER, L ;
DVORAK, HF ;
SENGER, DR .
MOLECULAR BIOLOGY OF THE CELL, 1992, 3 (02) :211-220
[3]  
DVORAK HF, 1988, AM J PATHOL, V133, P95
[4]   PITUITARY FOLLICULAR CELLS SECRETE A NOVEL HEPARIN-BINDING GROWTH-FACTOR SPECIFIC FOR VASCULAR ENDOTHELIAL-CELLS [J].
FERRARA, N ;
HENZEL, WJ .
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 1989, 161 (02) :851-858
[5]   Regulation of transport pathways in tumor vessels: Role of tumor type and microenvironment [J].
Hobbs, SK ;
Monsky, WL ;
Yuan, F ;
Roberts, WG ;
Griffith, L ;
Torchilin, VP ;
Jain, RK .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1998, 95 (08) :4607-4612
[6]  
Kopecek J., 1991, US Patent, Patent No. [5 037 883, 5037883]
[7]  
Lankelma J, 1999, CLIN CANCER RES, V5, P1703
[8]  
Lu ZR, 1999, MACROMOL CHEM PHYSIC, V200, P2022, DOI 10.1002/(SICI)1521-3935(19990901)200:9<2022::AID-MACP2022>3.0.CO
[9]  
2-Y
[10]   CONJUGATES OF ANTICANCER AGENTS AND POLYMERS - ADVANTAGES OF MACROMOLECULAR THERAPEUTICS INVIVO [J].
MAEDA, H ;
SEYMOUR, LW ;
MIYAMOTO, Y .
BIOCONJUGATE CHEMISTRY, 1992, 3 (05) :351-362